Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes.

Authors:
Dr Anirban Majumder, MBBS, MD, DM.
Dr Anirban Majumder, MBBS, MD, DM.
KPC Medical College, Kolkata, India
Professor
Endocrinology
KOLKATA, West Bengal | India
Dr Sanjay Chatterjee, MD
Dr Sanjay Chatterjee, MD
Apollo Gleneagles Hospital
Consultant Diabetologist
Diabetology
Kolkata, West Bengal | India

Sci Rep 2015 Jan 9;5:7706. Epub 2015 Jan 9.

Consultant Endocrinologist, Apollo Gleneagles Hospital, 58 Canal Circular Road, Kolkata 700054, India.

Cardiovascular risk reduction is an important issue in the management of patients with Type 2 diabetes mellitus. Peroxisome proliferator activated receptor (PPAR) agonists favourably influence glycaemic and lipid parameters in patients with Type 2 diabetes and a dual PPAR agonist is expected to have favourable effect on both parameters. In this study we have analyzed the effect of Saroglitazar, a novel dual PPAR alpha &gamma agonist, on glycaemic and lipid parameters in Indian patients with Type 2 diabetes. After a mean follow-up period of 14 weeks in 34 patients, treatment with Saroglitazar, in a dose of 4 mg daily, resulted in significant improvement in both glycaemic and lipid parameters. There were significant mean reductions of fasting plasma glucose (36.71 mg/dl; p = 0.0007), post-prandial plasma glucose (66.29 mg/dl; p = 0.0005), glycosylated haemoglobin (1.13%; p < 0.0001), total cholesterol (48.16 mg/dl; p < 0.0001), low- density lipoprotein cholesterol (24.04 mg/dl; p = 0.0048), triglyceride (192.78 mg/dl; p = 0.0001), non-high density lipoprotein cholesterol (48.72 mg/dl; p < 0.0001) and the ratio of triglyceride and high density lipoprotein cholesterol (5.30; p = 0.0006). There was no significant change in body weight, blood pressure, high-density lipoprotein cholesterol and serum creatinine.

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep07706DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287720PMC

Still can't find the full text of the article?

We can help you send a request to the authors directly.
January 2015
52 Reads
3 Citations
5.080 Impact Factor

Article Mentions


Provided by Crossref Event Data
wikipedia
Wikipedia: Saroglitazar
April 20, 2017, 10:31 am EST

Publication Analysis

Top Keywords

lipid parameters
16
patients type
16
glycaemic lipid
16
type diabetes
16
lipoprotein cholesterol
16
density lipoprotein
12
mg/dl 00001
12
indian patients
8
dual ppar
8
parameters indian
8
plasma glucose
8
mg/dl
6
cholesterol
5
patients
5
parameters
5
dose daily
4
saroglitazar dose
4
treatment saroglitazar
4
4872 mg/dl
4
00001 ratio
4

References

(Supplied by CrossRef)
Article in Clinical Diabetes
MP Solano et al.
Clinical Diabetes 2006
Article in Endocr Pract
AJ Garber et al.
Endocr Pract 2013
Article in Diabetes Vasc Dis Res
SJ Nicholls et al.
Diabetes Vasc Dis Res 2012
Article in N Engl J Med
HB Rubins et al.
N Engl J Med 1999
Article in Diabetes Technol Ther
RH Jani et al.
Diabetes Technol Ther 2014
Article in Diabetes Care
R Boizel et al.
Diabetes Care 2000
Article in Circulation
NJ Stone et al.
Circulation 2014
Article in Lancet
A Keech et al.
Lancet 2005
Article in Ann Intern Med
CR Elley et al.
Ann Intern Med 2013

Similar Publications